News

Article

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe-11-01-2005
Volume17
Issue 11

FDA commissioner quits

Lester Crawford, FDA's top man, has resigned explaining that it was time to step down — despite only being promoted to commissioner earlier this year.

Lester Crawford, FDA's top man, has resigned explaining that it was time to step down — despite only being promoted to commissioner earlier this year. Crawford's tenure at FDA finished with increasing criticism following problems with products and argued decisions. He now faces an enquiry into his resignation by the US Senate Health Committee.

Some of the problems during the erstwhile commissioner's term have caused embarrassment for FDA, such as the safety problems that caused Vioxx to be pulled off the market; mounting recalls of malfunctioning heart devices; and the indefinite postponement of nonprescription emergency contraception sales.

Crawford's experience in food safety was the reason he was elevated by President George Bush from acting commissioner as a preventative measure against bioterrorism. His place has been taken by former National Cancer Institute director and friend of President Bush, Andrew von Eschenbach.

www.fda.gov

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content